ClearSign Combustion Corporation — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. The filing identifies the registrant as ClearSign Combustion Corporation; the request metadata names ClearSign Technologies Corp.
Business context
ClearSign was a development-stage company developing combustion technologies intended to improve energy efficiency and emissions control. It had not begun planned principal operations and had generated no operating revenue since its January 2008 inception.
Financial results and position
| Metric | Q1 2012 / March 31, 2012 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $264,523 | $22,919 in Q1 2011 |
| General and administrative expense | $599,725 | $869,268 in Q1 2011 |
| Total operating expenses | $864,248 | $892,187 in Q1 2011 |
| Net loss | $864,706 | $892,187 in Q1 2011 |
| Cash from operating activities | $(621,411) | $(96,407) in Q1 2011 |
| Cash | $241,471 | $929,962 at December 31, 2011 |
| Working capital | $(189,925) | $622,661 at December 31, 2011 |
| Total liabilities | $1,410,793 | $761,738 at December 31, 2011 |
Basic and diluted loss per share was $0.17, compared with $0.29 in Q1 2011. Gross margin and operating margin are not meaningful because the company reported no revenue. The company had a $35,017 promissory note balance, payable in monthly installments through November 2012, and $881,639 in accounts payable.
Changes and unusual items
- Operating expenses declined about $28,000 year over year. R&D expense rose about $242,000 with increased personnel and research activity; G&A fell about $269,000, partly because Q1 2011 included a nonrecurring $675,000 stock-paid consulting expense to MDB Capital Group.
- Cash used in operations increased to $621,411, driven in part by the quarterly loss and a $507,457 increase in prepaid expenses. Investing activities used $54,430, primarily for fixed assets and patents; financing activities used $12,650 for note principal payments.
- At March 31, the company reported stockholders’ equity of $75,359 and accumulated development-stage losses of $5,354,944.
Outlook, risks and contingencies
- After quarter-end, the company completed an IPO and overallotment in April and May 2012, issuing 3.45 million shares at $4.00 per share. Gross proceeds were $13.8 million and net proceeds approximately $10.9 million. Management expected proceeds to fund operations through at least April 2014.
- Management planned to use approximately $5 million for R&D and related capital expenditures, $1 million for intellectual-property protection, $1.25 million to explore market opportunities, and the balance for working capital and general corporate purposes. It anticipated annual capital expenditures of $0.5–$1.0 million and potentially adding 20–30 employees, depending on development needs.
- The 2011 auditor’s report included a going-concern explanatory paragraph. The company cautioned that commercialization, customer acceptance, future revenue, profitability, and additional financing were uncertain; if financing or implementation plans fail, operations could be curtailed or suspended.
- Perkins Coie LLP reported a related party’s claimed right to acquire 25,250 shares at $0.02 per share under a 2007 engagement letter. The company disputed the claim, citing a 2011 settlement, and was continuing its review. No other legal proceedings were reported for the quarter.
- The company disclosed approximately $551,000 in minimum future office and laboratory lease payments at March 31, 2012, in addition to triple-net operating costs. It also disclosed potential CEO severance obligations and annual independent-director compensation arrangements that commence after the stock began public trading.
Important facts for investors to verify
- Confirm the post-quarter IPO net proceeds, offering costs, and actual cash runway against subsequent filings.
- Track cash burn, working-capital position, payables, and the remaining promissory-note payments.
- Assess progress toward technology validation, co-development partnerships, commercialization, and first revenue.
- Review the status and potential financial or share-dilution impact of the Perkins Coie-related share claim and IPO warrants.
- The cover page marks “No” for having filed all required reports during the preceding 12 months; verify the filing-status disclosure and any implications.